Data Sheet (Cat.No.T67955)

TargetMol

Ensaculin

Chemical Properties



CAS No. : 155773-59-4

Formula: C26H32N2O5

Molecular Weight: 452.54

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Ensaculin (Anseculin), a novel benzopyrone partially substituted with piperazine, showed memory-enhancing effects in passive and conditioned avoidance paradigms in normal and artificially amnesic rodents. It showed neuroprotective activity in a model of NMDA toxicity and neurotrophic effects in primary cultured rat brain cells.Ensaculin can be used for the treatment of dementia.
Targets(IC50)	Others,5-HT Receptor,Adrenergic Receptor,Dopamine Receptor,iGluR
In vivo	Ensaculin (0.1, 1 and 10 mg/kg; i.p.; Wistar rats; 20 min after the onset of glutamate perfusion) significantly antagonized the formation of 2,3-DHBA, to values of 60.5% and 56.7% of control levels, respectively. Ensaculin may be useful in the treatment of neurodegenerative disorders associated with elevated hydroxyl free radicals and excitotoxicity.[1]

Solubility Information

Solubility	DMSO: 42.6 mg/mL (94.14 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2097 mL	11.0487 mL	22.0975 mL
5 mM	0.4419 mL	2.2097 mL	4.4195 mL
10 mM	0.221 mL	1.1049 mL	2.2097 mL
50 mM	0.0442 mL	0.221 mL	0.4419 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Teismann P, et al. Comparison of the novel drug Ensaculin with MK-801 on the reduction of hydroxyl radical production in rat striatum after local application of glutamate. Brain Res. 2000;857(1-2):165-17

Teismann P, et al. Effects of ensaculin on dopamine metabolite levels and K(+)-induced glutamate release. Eur J Pharmacol. 2000;398(2):247-250.

Hoerr R, et al. Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002;8 (2):143-158.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481